First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC) Meeting Abstract
| Authors: | Wainberg, Z. A.; Diamond, J. R.; Curigliano, G.; Deva, S.; Bendell, J. C.; Han, S. W.; Kalyan, A.; Naidoo, J.; Kim, R. D.; Patel, S. P.; Kourtesis, P.; Li, X.; Ascierto, M.; Song, X.; Das, M.; Segal, N. H. |
| Abstract Title: | First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC) |
| Meeting Title: | 2020 Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2020 Jan 23-25 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-02-01 |
| Language: | English |
| ACCESSION: | WOS:000530922700122 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.4_suppl.128 |
| Notes: | Meeting Abstract: 128 -- Source: Wos |
